drugset / Trial / NCT00586209
L-Glutamine Therapy for Sickle Cell Anemia
Phase 2
Terminated
15 enrolled
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Emmaus Medical, Inc. · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary purpose is to evaluate the effect of L-glutamine therapy on exercise endurance and breath by breath exercise response of sickle cell anemia patients The secondary purpose is to assess the effect of L-glutamine on incidence of painful crises; level of chronic pain, and amount of daily requirement for narcotics.
Timeline
- Start
- 2004-02-06
- Primary completion
- 2008-08-27
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glutamine | Other / unclassified | 5 g | Oral |
| Subject | Glutamine | Other / unclassified | 10 g | Oral |
| Subject | Glutamine | Other / unclassified | 15 g | Oral |